Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Research and Markets
DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/8tn4zn/biomarker) has announced the addition of the "Biomarker Partnering Terms and Agreements" report to their offering.
The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in biomarker dealmaking
2.2. Biomarker partnering over the years
2.3. Bigpharma biomarker dealmaking activity
2.4. Most active biomarker dealmakers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7. Biomarker partnering by stage of development
2.8 Average deal terms for biomarkers
2.8.1 Biomarker headline values
2.8.2 Biomarker upfront payments
2.8.3 Biomarker milestone payments
2.8.4 Biomarker royalty rates
Chapter 3 - Leading biomarker deals
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving bigpharma
Chapter 4 - Big pharma biomarker deals
4.2. How to use big pharma biomarker partnering deals
4.3. Big pharma biomarker partnering company profiles
Chapter 5 - Biomarker dealmaking directory
5.2. By stage of development
5.3. By deal type
Chapter 6 - Biomarker dealmaking by technology type
6.2. Deals by biomarker type
Chapter 7 - Biomarker partnering resource center
7.1. Online biomarker partnering
7.2. Biomarker partnering events
7.3. Further reading on biomarker dealmaking
For more information visit http://www.researchandmarkets.com/research/8tn4zn/biomarker
Laura Wood , +353-1-481-1716, firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.